# Package: nlmixr2data (via r-universe)

July 1, 2024

July 1, 2024
Title Nonlinear Mixed Effects Models in Population PK/PD, Data
Version 2.0.9
Description Datasets for 'nlmixr2' and 'rxode2'. 'nlmixr2' is used for fitting and comparing nonlinear mixed-effects models in differential equations with flexible dosing information commonly seen in pharmacokinetics and pharmacodynamics (Almquist, Leander, and Jirstrand 2015 <doi:10.1007 s10928-015-9409-1="">). Differential equation solving is by compiled C code provided in the 'rxode2' package (Wang, Hallow, and James 2015 <doi:10.1002 psp4.12052="">).</doi:10.1002></doi:10.1007>
License GPL (>= 3)
Encoding UTF-8
<b>Roxygen</b> $list(markdown = TRUE)$
RoxygenNote 7.2.3
<b>Depends</b> R (>= 2.10)
LazyData true
<pre>BugReports https://github.com/nlmixr2/nlmixr2data/issues/</pre>
<pre>URL https://nlmixr2.github.io/nlmixr2data/,</pre>
https://github.com/nlmixr2/nlmixr2data/
Repository https://nlmixr2.r-universe.dev
RemoteUrl https://github.com/nlmixr2/nlmixr2data
RemoteRef HEAD
<b>RemoteSha</b> f7bd1f7b1b893f30b8239420af277f3275139611
Contents
Bolus_1CPT

Bolus\_1CPT

Bolus	s_1CPT 1 Compartment Model Simulated Data from ACOP 2016	
Index		30
	wbcSim	
	warfarin	
	Wang2007	
	theo_sd	
	theo_md	
	rats	
	pump	
	pheno_sd	
	Oral_2CPTMM	
	Oral_2CPT	
	Oral_1CPTMM	
	Oral_1CPT	
	nmtest	
	nimoData	
	metabolite	
	mavoglurant	
	invgaussian	
	Infusion_2CPTMM	
	Infusion_2CPT	
	Infusion_1CPTMM	
	Infusion_1CPT	- 7

# Description

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

# Usage

Bolus\_1CPT

## **Format**

A data frame with 7,920 rows and 14 columns

**ID** Simulated Subject ID

**TIME** Simulated Time

DV Simulated Dependent Variable

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

Bolus\_1CPTMM 3

EVID NONMEM Event ID

**DOSE** Dose

V Individual Simulated Volume

CL Individual Clearance

SS Steady State

II Interdose Interval

SD Single Dose Flag

**CMT** Compartment

#### **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

# Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

# See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Bolus\_1CPTMM

1 Compartment Model w/ Michaelis-Menten Elimination

## **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

# Usage

Bolus\_1CPTMM

4 Bolus\_1CPTMM

## **Format**

A data frame with 7,920 rows and 14 columns

**ID** Simulated Subject ID

**TIME** Simulated Time

**DV** Simulated Dependent Variable

**LNDV** Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

EVID NONMEM Event ID

**DOSE** Dose

V Individual Simulated Volume

VM Individual Vm constant

KM Individual Km constant

SD Single Dose Flag

**CMT** Compartment

## **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

# Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

## See Also

Other nlmixr2 datasets: Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Bolus\_2CPT 5

Bolus\_2CPT

2 Compartment Model

# **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

## Usage

Bolus\_2CPT

#### **Format**

A data frame with 7,920 rows and 16 columns

**ID** Simulated Subject ID

**TIME** Simulated Time

**DV** Simulated Dependent Variable

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

**EVID** NONMEM Event ID

**DOSE** Dose

V1 Individual Central Compartment Volume

CL Individual Clearance

Q Individual Between Compartment Clearance

**V2** Periperial Volume

SS Steady State Flag

II Interdose interval

SD Single Dose Flag

**CMT** Compartment Indicator

# **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were

6 Bolus\_2CPTMM

compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Bolus\_2CPTMM

2 Compartment Model with Michaelis-Menten Clearance

## **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

# Usage

Bolus\_2CPTMM

## **Format**

A data frame with 7,920 rows and 15 columns

**ID** Simulated Subject ID

**TIME** Simulated Time

**DV** Simulated Dependent Variable

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

**EVID** NONMEM Event ID

**DOSE** Dose

V Individual Central Compartment Volume

VM Individual Vmax

KM Individual Km

Q Individual Q

V2 Individual Peripheral Compartment Volume

**SD** Single Dose Flag

**CMT** Compartment Indicator

Infusion\_1CPT 7

## **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## **Source**

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

#### See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Infusion\_1CPT

1 Compartment Model Simulated Data from ACOP 2016

## **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

# Usage

Infusion\_1CPT

## **Format**

A data frame with 7,920 rows and 14 columns

**ID** Simulated Subject ID

TIME Simulated Time

**DV** Simulated Dependent Variable

**LNDV** Simulated log(Dependent Variable)

MDV Missing DV data item

8 Infusion\_1CPTMM

**AMT** Dosing AMT

EVID NONMEM Event ID

**DOSE** Dose

V Individual Simulated Volume

**CL** Individual Clearance

SS Steady State

II Interdose Interval

SD Single Dose Flag

**RATE NONMEM Rate** 

CMT Compartment

#### **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

# See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Infusion\_1CPTMM

1 Compartment Model w/MM elimination Simulated Data from ACOP 2016

## **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

Infusion\_1CPTMM 9

## Usage

Infusion\_1CPTMM

## **Format**

A data frame with 7,920 rows and 14 columns

ID Simulated Subject ID

**TIME** Simulated Time

**DV** Simulated Dependent Variable

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

**AMT** Dosing AMT

**EVID** NONMEM Event ID

**DOSE** Dose

V Individual Simulated Volume

KM Individual Km constant

VM Individual Vm constant

**SD** Single Dose Flag

**RATE NONMEM Rate** 

**CMT** Compartment

### **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

# See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

10 Infusion\_2CPT

Infusion\_2CPT

2 Compartment Model with Infusion Simulated Data from ACOP 2016

# **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

# Usage

Infusion\_2CPT

# **Format**

A data frame with 7,920 rows and 17 columns

**ID** Simulated Subject ID

**TIME** Simulated Time

**DV** Simulated Dependent Variable

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

**EVID** NONMEM Event ID

**DOSE** Dose

V Individual Simulated Volume

CL Individual Clearance

Q Individual Inter-compartmental Clearance

V2 Individual Peripheral Volume

SS Steady State

**RATE NONMEM Rate** 

II Interdose Interval

SD Single Dose Flag

CMT Compartment

## **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for

Infusion\_2CPTMM 11

all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Infusion\_2CPTMM

2 Compartment Model w/MM elimination Simulated Data from ACOP 2016

# **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

# Usage

Infusion\_2CPTMM

## **Format**

A data frame with 7,920 rows and 14 columns

**ID** Simulated Subject ID

TIME Simulated Time

**DV** Simulated Dependent Variable

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

**EVID** NONMEM Event ID

**DOSE** Dose

Q Individual Between Compartment Clearance

V Individual Simulated Volume

12 invgaussian

V2 Individual Peripheral Volume

KM Individual Km constant

VM Individual Vm constant

SD Single Dose Flag

**RATE NONMEM Rate** 

**CMT** Compartment

## **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

invgaussian

Inverse Guassian absorption model

# Description

Inverse Guassian absorption model

# Usage

invgaussian

mavoglurant 13

# **Format**

A data frame with 32 rows and 6 columns

time Time of observation

cp Concentration

# Source

Figure 9.7 in D'Argenio DZ, Schumitzky A, and Wang X (2009). "ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software".

mavoglurant

Mavoglurant PK data

# Description

This was used in a full PBPK model. This one was published for mavoglurant (Wendling et al. 2016).

## Usage

mavoglurant

# **Format**

A data frame with 2,678 rows by 14 columns

**ID** Subject ID

**CMT** Compartment Number

EVID Event ID

MDV Missing DV

DV Dependent Variable, Mavoglurant

AMT Dose Amount Keyword

TIME Time (hr)

**DOSE** Dose

OCC Occasion

RATE Rate

AGE Age

SEX Sex

WT Weight

HT Height

14 metabolite

## **Source**

Wendling et al. 2016

# See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

metabolite

Parent/Metabolite dataset

# Description

Parent/Metabolite dataset

## Usage

metabolite

# **Format**

A data frame with 32 rows and 6 columns

time Time of observation

y1 Parent Concentration

y2 Metabolite Concentration

# **Source**

D'Argenio DZ, Schumitzky A, and Wang X (2009). "ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software".

nimoData 15

nimoData

Nimotuzumab PK data

# Description

**ID** Subject ID

TIME Time (hrs)

AMT Dose Amount Keyword

**RATE** Rate

DV Dependent Variable, Nimotuzumab

TAD Time After Dose

**CMT** Compartment Number

**OCC** Occasion

MDV Missing DV

EVID Event ID

WGT Weight

BSA Body Surface Area

AGE Age

**HGT** Height

**DOS** Dose

# Usage

nimoData

# **Format**

A data frame with 441 rows by 15 columns

## **Source**

Rodriguez-Vera et al. 2015

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

16 nmtest

nmtest

One compartment test dataset showing NONMEM 7.4.3 output

# **Description**

This is a example dataset originally created to show how similar mrgsolve and NONMEM were (See ).

## Usage

nmtest

## **Format**

A data frame with 7,157 rows and 15 columns

id NONMEM id

time NONMEM time

cp NONMEM cp output from 7.4.3

cmt cmt specification 1=depot, 2=central

amt Nonmem dose

evid NONMEM Event ID

ii Interdose Interval

ss Steady state flag

addl Individual Clearance

rate Rate of the infusion

lagt Lag time

bioav Bioavailability

rat2 Modeled rate when mode == 1

**dur2** Duration when mode == 2

**mode** Mode = 0 is no modification, modeled rate when mode=1 and modeled duration when mode=2

# **Details**

The original dataset was created by Kyle Baron and is composed of id<100 the id>100 are modifications by Matthew Fidler to benchmark steady state infusions with lag times and other uncommon features.

Note that rxode2/nlmixr2 will not always match these behaviors by default, we choose behaviors that we believe make sense. There are options to make rxode2/nlmixr2 behave more like NONMEM. However behaviors we believe are wrong we do not support.

Oral\_1CPT 17

## Author(s)

Kyle Baron & Matthew Fidler

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Oral\_1CPT

1 Compartment Model with Oral Absorption Simulated Data from ACOP 2016

## **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

# Usage

Oral\_1CPT

## Format

A data frame with 7,920 rows and 15 columns

ID Simulated Subject ID

TIME Simulated Time

DV Simulated Dependent Variable

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

EVID NONMEM Event ID

**DOSE** Dose

V Individual Simulated Volume

CL Individual Clearance

KA Individual Ka

SS Steady State

II Interdose Interval

SD Single Dose Flag

**CMT** Compartment

18 Oral\_1CPTMM

## **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

#### Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Oral_1CPTMM	1 Compartment Model w/ Oral Absorption & Michaelis-Menten Elimination

## **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

## Usage

Oral\_1CPTMM

## **Format**

A data frame with 7,920 rows and 14 columns

**ID** Simulated Subject ID

**TIME** Simulated Time

**DV** Simulated Dependent Variable

Oral\_1CPTMM 19

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

**EVID** NONMEM Event ID

**DOSE** Dose

KA Individual Absorption constant

V Individual Simulated Volume

VM Individual Vm constant

KM Individual Km constant

SD Single Dose Flag

**CMT** Compartment

## **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

# See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

20 Oral\_2CPT

Oral\_2CPT 2 Compartment Model with Oral Absorption Simulated Data from ACOP 2016

# **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

# Usage

Oral\_2CPT

## **Format**

A data frame with 7,920 rows and 15 columns

**ID** Simulated Subject ID

TIME Simulated Time

**DV** Simulated Dependent Variable

LNDV Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

EVID NONMEM Event ID

**DOSE** Dose

Q Individual Inter-compartmental Clearance

V1 Individual Simulated Volume

V2 Individual Simulated Peripheral Volume

**CL** Individual Clearance

KA Individual Ka

SS Steady State

II Interdose Interval

SD Single Dose Flag

CMT Compartment

## **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for

Oral\_2CPTMM 21

all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## **Source**

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

Oral\_2CPTMM

1 Compartment Model w/ Oral Absorption & Michaelis-Menten Elimination

# **Description**

This is a simulated dataset from the ACOP 2016 poster. All Datasets were simulated with the following methods.

## Usage

Oral\_2CPTMM

# **Format**

A data frame with 7,920 rows and 14 columns

**ID** Simulated Subject ID

**TIME** Simulated Time

**DV** Simulated Dependent Variable

**LNDV** Simulated log(Dependent Variable)

MDV Missing DV data item

AMT Dosing AMT

EVID NONMEM Event ID

**DOSE** Dose

KA Individual Absorption constant

pheno\_sd

V1 Individual Simulated Volume

V2 Individual Simulated Perhipheral Volume

Q Individual Inter-compartmental Clearance

VM Individual Vm constant

KM Individual Km constant

SD Single Dose Flag

**CMT** Compartment

## **Details**

Richly sampled profiles were simulated for 4 different dose levels (10, 30, 60 and 120 mg) of 30 subjects each as single dose (over 72h), multiple dose (4 daily doses), single and multiple dose combined, and steady state dosing, for a range of test models: 1- and 2-compartment disposition, with and without 1st order absorption, with either linear or Michaelis-Menten (MM) clearance(MM without steady state dosing). This provided a total of 42 test cases. All inter-individual variabilities (IIVs) were set at 30%, residual error at 20% and overlapping PK parameters were the same for all models. A similar set of models was previously used to compare NONMEM and Monolix4. Estimates of population parameters, standard errors for fixed-effect parameters, and run times were compared both for closed-form solutions and using ODEs. Additionally, a sparse data estimation situation was investigated where 500 datasets of 600 subjects each (150 per dose) were generated consisting of 4 random time point samples in 24 hours per subject, using a first-order absorption, 1-compartment disposition, linear elimination model.

## Source

Schoemaker R, Xiong Y, Wilkins J, Laveille C, Wang W. nlmixr2: an open-source package for pharmacometric modelling in R. ACOP 2016

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

pheno\_sd

Single Dose Phenobarbitol PK/PD

## **Description**

This is from a PK study in neonatal infants. They received multiple doses of phenobarbital for seizure prevention.

# Usage

pheno\_sd

pheno\_sd 23

## **Format**

A data frame with 744 rows and 8 columns

ID Infant ID

TIME Time (hr)

AMT Dose (ug/kg)

WT Weight (kg)

**APGR** A 5-minute Apgar score to measure infant health

DV The concentration of phenobarbitol in the serum (ug/mL)

MDV If the dependent variable (DV) is missing; 0 for observations, 1 for doses

**EVID** Event ID

## **Details**

The data were originally given in Grasela and Donn(1985) and are analyzed in Boeckmann, Sheiner and Beal (1994), in Davidian and Giltinan (1995), and in Littell et al. (1996).

### Source

Pinheiro, J. C. and Bates, D. M. (2000), Mixed-Effects Models in S and S-PLUS, Springer, New York. (Appendix A.23)

Davidian, M. and Giltinan, D. M. (1995), Nonlinear Models for Repeated Measurement Data, Chapman and Hall, London. (section 6.6)

Grasela and Donn (1985), Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data, Developmental Pharmacology and Therapeutics, 8, 374-383.

Boeckmann, A. J., Sheiner, L. B., and Beal, S. L. (1994), NONMEM Users Guide: Part V, University of California, San Francisco.

Littell, R. C., Milliken, G. A., Stroup, W. W. and Wolfinger, R. D. (1996), SAS System for Mixed Models, SAS Institute, Cary, NC.

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, rats, theo\_md, theo\_sd, warfarin, wbcSim

24 rats

pump

Pump failure example dataset

# Description

The records the number of failures and operation time for groups of 10 pumps.

# Usage

pump

## **Format**

A data frame with 10 rows and 5 columns

- y Number of pump failures
- t Failure Time

**group** Continuous Operation (=1) or Intermittent Operation(=2)

**ID** ID for group of 10 pumps

logtstd Centered operation times

## **Source**

 $https://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/viewer.htm \#statug\_nlmixed\_sect040.htm$ 

## References

Gaver, D. P. and O'Muircheartaigh, I. G. (1987), "Robust Empirical Bayes Analysis of Event Rates," Technometrics, 29, 1-15.

rats

Pregnant Rat Diet Experiment

# **Description**

16 pregnant rats have a control diet, and 16 have a chemically treated diet. The litter size for each rat is recorded after 4 and 21 days. This dataset is used in the SAS Probit-model with binomial data, and saved in the nlmixr2 package as rats.

# Usage

rats

theo\_md 25

## **Format**

A data frame with 32 rows and 6 columns

**trt** Treatment; c= control diet; t=treated diet

m Litter size after 4 days

x Litter size after 21 days

**x1** Indicator for trt=c

**x2** Indicator for trt=t

ID Rat ID

## Source

https://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/viewer.htm#statug\_nlmixed\_sect040.htm

## References

Weil, C.S., 1970. Selection of the valid number of sampling units and a consideration of their combination in toxicological studies involving reproduction, teratogenesis or carcinogenesis. Fd. Cosmet. Toxicol. 8, 177-182.

Williams, D.A., 1975. The analysis of binary responses from toxicological experiments involving reproduction and teratogenicity. Biometrics 31, 949-952.

McCulloch, C. E. (1994), "Maximum Likelihood Variance Components Estimation for Binary Data," Journal of the American Statistical Association, 89, 330 - 335.

Ochi, Y. and Prentice, R. L. (1984), "Likelihood Inference in a Correlated Probit Regression Model," Biometrika, 71, 531-543.

# See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, theo\_md, theo\_sd, warfarin, wbcSim

theo\_md

Multiple dose theophylline PK data

# Description

This data set starts with the day 1 concentrations of the theophylline data that is included in the nlme/NONMEM. After day 7 concentrations were simulated with once a day regimen for 7 days (QD).

# Usage

theo\_md

26 theo\_sd

## **Format**

A data frame with 348 rows by 7 columns

**ID** Subject ID

TIME Time (hr)

**DV** Dependent Variable, theophylline concentration (mg/L)

AMT Dose Amount (kg)

**EVID** rxode2/nlmixr2 event ID (not NONMEM event IDs)

**CMT** Compartment number

WT Body weight (kg)

#### Source

NONMEM/nlme

#### See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_sd, warfarin, wbcSim

theo\_sd

Multiple dose theophylline PK data

# Description

This data set is the day 1 concentrations of the theophylline data that is included in the nlme/NONMEM.

# Usage

theo\_sd

## **Format**

A data frame with 144 rows by 7 columns

**ID** Subject ID

**TIME** Time (hr)

**DV** Dependent Variable, theophylline concentration (mg/L)

**AMT** Dose Amount (mg)

**EVID** rxode2/nlmixr2 event ID (not NONMEM event IDs)

**CMT** Compartment Number

WT Body weight (kg)

Wang2007 27

## Source

NONMEM/nlme

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, warfarin, wbcSim

Wang2007

Simulated Data Set for comparing objective functions

## **Description**

This is a simulated dataset from Wang2007 where various NONMEM estimation methods (Laplace FO, FOCE with and without interaction) are described.

## Usage

Wang2007

## **Format**

A data frame with 20 rows and 3 columns

**ID** Simulated Subject ID

Time Simulated Time

Y Simulated Value

## Source

Table 1 from Wang, Y *Derivation of Various NONMEM estimation methods*. J Pharmacokinet Pharmacodyn (2007) 34:575-593.

# See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin, wbcSim

28 warfarin

warfarin

Warfarin PK/PD data

# **Description**

Warfarin PK/PD data

# Usage

warfarin

## **Format**

A data frame with 519 rows and 9 columns

```
id Patient identifier (n=32)
```

time Time (h)

amt Total drug administered (mg)

dv Warfarin concentrations (mg/L) or PCA measurement

dvid Dependent identifier Information (cp: Dose or PK, pca: PCA, factor)

evid Event identifier

wt Weight (kg)

age Age (yr)

sex Sex (male or female, factor)

## Source

Funaki T, Holford N, Fujita S (2018). Population PKPD analysis using nlmixr2 and NONMEM. PAGJA 2018

## References

O'Reilly RA, Aggeler PM, Leong LS. Studies of the coumarin anticoagulant drugs: The pharmacodynamics of warfarin in man. Journal of Clinical Investigation 1963; 42(10): 1542-1551

O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs Initiation of warfarin therapy without a loading dose. Circulation 1968; 38: 169-177.

# See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, wbcSim

wbcSim 29

wbcSim

Simulated Friberg Myelosuppression model (Yuan Xiong)

# Description

**ID** Subject ID

TIME Time (hrs)

**RATE** Rate

AMT Dose Amount Keyword

DV Dependent Variable, WBC

**CMT** Compartment Number

V2I Input Peripheral Volume

V1I Input Central Volume

V1I Input Clearance

EVID nlmixr2/rxode2 classic evid

# Usage

wbcSim

# **Format**

An object of class data. frame with 280 rows and 10 columns.

# Source

Simulated Data for WBC pac ddmore model

## See Also

Other nlmixr2 datasets: Bolus\_1CPTMM, Bolus\_1CPT, Bolus\_2CPTMM, Bolus\_2CPT, Infusion\_1CPTMM, Infusion\_1CPT, Infusion\_2CPTMM, Infusion\_2CPT, Oral\_1CPTMM, Oral\_1CPT, Oral\_2CPTMM, Oral\_2CPT, Wang2007, mavoglurant, nimoData, nmtest, pheno\_sd, rats, theo\_md, theo\_sd, warfarin

# **Index**

* datasets	Oral_1CPTMM, 18
Bolus_1CPT, 2	Oral_2CPT, 20
Bolus_1CPTMM, 3	Oral_2CPTMM, 21
Bolus_2CPT, 5	pheno_sd, 22
Bolus_2CPTMM, 6	rats, 24
Infusion_1CPT, 7	theo_md, 25
Infusion_1CPTMM, 8	theo_sd, 26
Infusion_2CPT, 10	Wang2007, 27
Infusion_2CPTMM, 11	warfarin, 28
invgaussian, 12	wbcSim, 29
mavoglurant, 13	, .
metabolite, 14	Bolus_1CPT, 2, 4, 6–9, 11, 12, 14, 15, 17–19,
	21–23, 25–29
nimoData, 15	Bolus_1CPTMM, 3, 3, 6–9, 11, 12, 14, 15,
nmtest, 16	17–19, 21–23, 25–29
Oral_1CPTMM_18	Bolus_2CPT, 3, 4, 5, 7–9, 11, 12, 14, 15,
Oral_1CPTMM, 18	17–19, 21–23, 25–29
Oral_2CPT, 20	Bolus_2CPTMM, 3, 4, 6, 6, 8, 9, 11, 12, 14, 15,
Oral_2CPTMM, 21	17–19, 21–23, 25–29
pheno_sd, 22	
pump, 24	Infusion_1CPT, 3, 4, 6, 7, 7, 9, 11, 12, 14, 15,
rats, 24	17–19, 21–23, 25–29
theo_md, 25	Infusion_1CPTMM, 3, 4, 6–8, 8, 11, 12, 14, 15,
theo_sd, 26	17–19, 21–23, 25–29
Wang2007, 27	Infusion_2CPT, 3, 4, 6–9, 10, 12, 14, 15,
warfarin, 28	17–19, 21–23, 25–29
wbcSim, 29	Infusion_2CPTMM, <i>3</i> , <i>4</i> , <i>6</i> – <i>9</i> , <i>11</i> , 11, <i>14</i> , <i>15</i> ,
* nlmixr2 datasets	17–19, 21–23, 25–29
Bolus_1CPT, 2	invgaussian, 12
Bolus_1CPTMM, 3	mayorlyment 2 4 6 0 11 12 12 15 17 10
Bolus_2CPT, 5	mavoglurant, 3, 4, 6–9, 11, 12, 13, 15, 17–19, 21–23, 25–29
Bolus_2CPTMM, 6	21-23, 23-29 metabolite, 14
<pre>Infusion_1CPT, 7</pre>	metabolite, 14
Infusion_1CPTMM, 8	nimoData, 3, 4, 6-9, 11, 12, 14, 15, 17-19,
Infusion_2CPT, 10	21–23, 25–29
Infusion_2CPTMM, 11	nmtest, 3, 4, 6–9, 11, 12, 14, 15, 16, 18, 19,
mavoglurant, 13	21–23, 25–29
nimoData, 15	,/
nmtest, 16	Oral_1CPT, 3, 4, 6-9, 11, 12, 14, 15, 17, 17,
Oral_1CPT, 17	19, 21–23, 25–29

INDEX 31

```
\begin{array}{c} \text{Oral\_1CPTMM, } 3, \, 4, \, 6-9, \, 11, \, 12, \, 14, \, 15, \, 17, \, 18, \\ 18, \, 21-23, \, 25-29 \\ \\ \text{Oral\_2CPT, } 3, \, 4, \, 6-9, \, 11, \, 12, \, 14, \, 15, \, 17-19, \\ 20, \, 22, \, 23, \, 25-29 \\ \\ \text{Oral\_2CPTMM, } 3, \, 4, \, 6-9, \, 11, \, 12, \, 14, \, 15, \, 17-19, \\ 21, \, 21, \, 23, \, 25-29 \\ \\ \text{pheno\_sd, } 3, \, 4, \, 6-9, \, 11, \, 12, \, 14, \, 15, \, 17-19, \, 21, \\ 22, \, 22, \, 25-29 \\ \\ \text{pump, } 24 \\ \end{array}
```

theo\_md, 3, 4, 6–9, 11, 12, 14, 15, 17–19, 21–23, 25, 25, 27–29 theo\_sd, 3, 4, 6–9, 11, 12, 14, 15, 17–19, 21–23, 25, 26, 26, 27–29

 $\begin{array}{c} {\rm Wang2007},\,3,\,4,\,6-9,\,11,\,12,\,14,\,15,\,17-19,\\ 21-23,\,25-27,\,27,\,28,\,29\\ {\rm warfarin},\,3,\,4,\,6-9,\,11,\,12,\,14,\,15,\,17-19,\\ 21-23,\,25-27,\,28,\,29\\ {\rm wbcSim},\,3,\,4,\,6-9,\,11,\,12,\,14,\,15,\,17-19,\\ 21-23,\,25-28,\,29\\ \end{array}$